Aclarion, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ACON Nasdaq 3840 www.aclarion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclarion, Inc.

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub - Jun 10th, 2026 5:00 am
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform - Jun 9th, 2026 5:00 am
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal - Jun 8th, 2026 5:05 am
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting - Jun 8th, 2026 5:00 am
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation - Jun 3rd, 2026 4:00 am
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study - Jun 1st, 2026 4:00 am
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal - May 28th, 2026 12:49 pm
Echo Lake Capital Offers To Acquire Aclarion Inc. - May 28th, 2026 6:00 am
Aclarion (ACON) Upgraded to Buy: Here's Why - May 19th, 2026 10:00 am
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 4:10 pm
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 5:05 pm
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment - May 7th, 2026 4:00 am
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. - May 6th, 2026 4:00 am
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - May 5th, 2026 4:00 am
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - Apr 30th, 2026 4:00 am
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan - Apr 28th, 2026 4:00 am
Aclarion Announces $2.5 Million Stock Repurchase Plan - Apr 22nd, 2026 6:30 am
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain - Apr 16th, 2026 4:47 am
Aclarion Receives Pinnacle Award for AI Innovation - Apr 14th, 2026 6:00 am
Aclarion Announces Agreement with Weill Cornell Medicine - Apr 8th, 2026 6:00 am